US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

317.11

+9.893.22%

Number of Gainers:5

Number of Losers:1

Number of Flat:- -

PE:- -

High:331.55

Open:307.30

Low:300.46

Close:307.22

Loading ...

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

JOHNNIE WALKER ESTABLISHES A NEW STANDARD IN DESIGN INNOVATION BY INTRODUCING BLUE LABEL ULTRA, THE WORLD'S LIGHTEST WHISKY BOTTLE

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week

Simply Wall St.

Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid

MT Newswires Live

Shares of bluebird bio Down 9% After Ayrmid Fails to Give Binding Offer

THOMSON REUTERS

BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer

bluebird bio Shares Down 7.9% at $4.12 Premarket After Ayrmid Fails to Give Binding Offer

THOMSON REUTERS

BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement

NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Beam Therapeutics (BEAM) Gets a Buy from Scotiabank

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":317.10944,"timestamp":1745265599999,"preClose":307.21762,"halted":0,"volume":16898450,"delay":0,"changeRate":0.032198,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":9.891815,"latestTime":"04-21 16:00:00 EDT","open":307.2963,"high":331.54907,"low":300.45554,"amount":174264766.020539,"amplitude":0.10121,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.601709,"peRate":-3.192578,"turnoverRate":0.029947,"increases":5,"decrements":1,"flats":0,"marketCap":6151854568,"floatMarketCap":5585620844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":331.54907,"amplitude":0.10121,"preClose":307.21762,"low":300.45554,"pbRate":"1.601709","latestPrice":317.10944,"volume":16898450,"delay":0,"open":307.2963,"prevYearClose":376.62552,"prevWeekClose":307.2176,"prevMonthClose":297.7814,"prevQuarterClose":297.7814,"fiveDayClose":309.6937,"twentyDayClose":360.9173,"sixtyDayClose":405.8632,"secType":"PLATE","market":"US","turnoverRate":0.029947,"peRate":-3.192578,"marketCap":6151854568,"floatMarketCap":5585620844,"timestamp":1745265599999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529062800","title":"CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It","url":"https://stock-news.laohu8.com/highlight/detail?id=2529062800","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529062800?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:00","pubTimestamp":1745240409,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG  is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this company have returned -8.4%, compared to the Zacks S&P 500 composite's -5.6% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 12.9%. The key question now is: What could be the stock's future direction?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.For the current fiscal year, the consensus earnings estimate of -$5.02 points to a change of -15.7% from the prior year. Over the last 30 days, this estimate has changed +2.1%.While earnings growth is arguably the most supe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-trending-130009505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","BK4556","AG","BK4585","BK4139","CRSP","BK4210","LU1861558580.USD","BK4611","BK4588"],"gpt_icon":0},{"id":"2528069814","title":"JOHNNIE WALKER ESTABLISHES A NEW STANDARD IN DESIGN INNOVATION BY INTRODUCING BLUE LABEL ULTRA, THE WORLD'S LIGHTEST WHISKY BOTTLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2528069814","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528069814?lang=en_us&edition=fundamental","pubTime":"2025-04-18 20:00","pubTimestamp":1744977600,"startTime":"0","endTime":"0","summary":"Johnnie Walker Blue Label Ultra is the newest offering from the lauded whisky brand, continuing its legacy of innovation by creating the world's lightest 70cl Scotch whisky glass bottle. Culminating a five year journey, the patented glass used to create the bottle will be open-sourced and royalty-free for all. To celebrate the launch, Johnnie Walker is hosting an exhibition during NYCxDesign in May, showcasing new works and historic collaborations that define the beloved brand. With only 888 bottles available worldwide, this limited edition bottles feature select 'ghost whiskies' from now-closed distilleries. NEW YORK, April 18, 2025 /PRNewswire/ --Johnnie Walker, the world's number one Scotch whisky, unveils Blue Label Ultra, a limited edition first-of-its kind, boundary-breaking innovation. Weighing just 6.3oz , Johnnie Walker Blue Label Ultra is the world's lightest 70cl Scotch whisky glass bottle. Using new, patented glass technology developed by Diageo's design team this lighter, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnnie-walker-establishes-standard-design-120000414.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnnie-walker-establishes-standard-design-120000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","BK4585","SMP","BK4556","DEO","BY","DGE.UK","BK4169","BK4559","BK4124","BLUE","BK4211","BK4588","BK4139"],"gpt_icon":0},{"id":"2528777475","title":"CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2528777475","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528777475?lang=en_us&edition=fundamental","pubTime":"2025-04-18 06:00","pubTimestamp":1744927214,"startTime":"0","endTime":"0","summary":"In the latest market close, CRISPR Therapeutics AG  reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other hand, the Dow registered a loss of 1.33%, and the technology-centric Nasdaq decreased by 0.13%.Shares of the company witnessed a loss of 9.92% over the previous month, trailing the performance of the Medical sector with its loss of 8.46% and the S&P 500's loss of 6.3%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.26 per share, which would represent year-over-year growth of 11.89%. At the same time, our most recent consensus estimate is projecting a revenue of $5.24 million, reflecting a 947.2% rise from the equivalent quarter last year.Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to ref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-220014129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRSP","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4556","BK4585","BK4210","BK4588","BK4611","AG"],"gpt_icon":0},{"id":"2528979774","title":"Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2528979774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528979774?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:59","pubTimestamp":1744887565,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-buy-from-bank-of-america-securities-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-buy-from-bank-of-america-securities-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2129689605.HKD","BK4611","IE00B7SZLL34.SGD","LU1280957306.USD","LU2133065610.SGD","IE00BBT3K403.USD","LU2129689514.USD","CRSP","LU0256863811.USD","LU1880398471.USD","LU0868494617.USD","LU0106831901.USD","BK4504","LU1366192091.USD","LU1201861165.SGD","IE00BKVL7J92.USD","LU1880398554.USD","AG","LU0971096721.USD","LU0683600562.USD","LU1718418525.SGD","LU2129689431.USD","LU0149725797.USD","LU0320765489.SGD","LU1861558580.USD","BK4210","BK4553","BK4585","LU0053666078.USD","LU1894683348.USD","LU0310800965.SGD","LU0417517546.SGD","LU0208291251.USD","LU0648001328.SGD","LU1074936037.SGD","LU1883839398.USD","LU1668664300.SGD","BK4534","BK4588","LU0787776722.HKD","LU0306806265.USD","BAC","IE00B19Z3581.USD","LU1791807156.HKD","BK4207","LU0477156797.USD","IE00BFXG1179.USD","LU0070302665.USD","BK4556","LU0314106906.USD"],"gpt_icon":0},{"id":"2528843276","title":"CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2528843276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528843276?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:02","pubTimestamp":1744826552,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced investor sentiment, potentially reflecting strategic shifts within the company. This price movement stands out against a backdrop of broader market gains, as major indexes faced downward pressure due to trade tensions between the U.S. and China, particularly affecting the technology sector. However, the market overall rose by 8% in the last seven days, suggesting that CRISPR's movements might align with or have been amplified by these broader trends.We've identified 1 weakness for CRISPR Therapeutics that you should be aware of.NasdaqGM:CRSP Earnings Per Share Growth as at Apr 2025. Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-nasdaqgm-crsp-sees-180232066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","LU1861558580.USD","CRSP","BK4611","BK4556","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2527407812","title":"Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2527407812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527407812?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:58","pubTimestamp":1744815503,"startTime":"0","endTime":"0","summary":"Bluebird Bio  said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle  and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Shares of Bluebird were down more than 6% in recent trading Wednesday.Price: 4.19, Change: -0.28, Percent Change: -6.26","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4578","BK4556","IE00BGHQF748.EUR","BLUE","BK4135","IE00B3QW5Z07.USD","CG","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2527248751","title":"Shares of bluebird bio Down 9% After Ayrmid Fails to Give Binding Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527248751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527248751?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:34","pubTimestamp":1744810457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU125:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BLUE","BK4578","BK4139"],"gpt_icon":0},{"id":"2527214083","title":"BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527214083?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:54","pubTimestamp":1744808091,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer** Shares of gene therapy firm Bluebird Bio BLUE.O down 8.7% at $4.08 premarket ** BLUE says privately held UK company Ayrmid Ltd has not submitted binding proposal to acquire it and has not obtained necessary financing ** Co in March received non-binding offer from Ayrmid for up to $110.5 million ** BLUE adds it continues to be at significant risk of defaulting on its loan covenants** Co's board reaffirms its recommendation in support of transaction with Carlyle CG.O and SK Capital, while recommending all stockholders tender into current agreement by May 2** BLUE agreed to be taken private by Carlyle and SK Capital Partners at discount in February** As of last close, stock has fallen 46.4% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","IE00B3QW5Z07.USD","BK4135","CG","IE00BGHQF748.EUR","BK4578","BLUE","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2527214233","title":"bluebird bio Shares Down 7.9% at $4.12 Premarket After Ayrmid Fails to Give Binding Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527214233?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:49","pubTimestamp":1744807746,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU1K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0},{"id":"2527216205","title":"BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216205?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:25","pubTimestamp":1744806321,"startTime":"0","endTime":"0","summary":"BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive EngagementApril 16 (Reuters) - bluebird bio Inc BLUE.O:BLUEBIRD BIO CONFIRM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA9ZCZVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BLUE","BK4556","BK4139"],"gpt_icon":0},{"id":"2527112168","title":"NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527112168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527112168?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:31","pubTimestamp":1744633871,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against Intellia Therapeutics Inc. ($NTLA) by Levi & Korsinsky on February 11, 2025. The plaintiffs (sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ntla-lawsuit-alert-class-action-lawsuit-against-intellia-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ntla-lawsuit-alert-class-action-lawsuit-against-intellia-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1861558580.USD","BK4535","BK4139","NTLA","LU1861559042.SGD","BK4556","BK4588"],"gpt_icon":0},{"id":"2526664088","title":"Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2526664088","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526664088?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:37","pubTimestamp":1744371466,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable to their trading decisions. A total of 7 investors have a majority stake in the company with 51% ownership. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Every investor in Beam Therapeutics Inc.  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. Put another way, the group faces the maximum upside potential .Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Our data indicates that hedge funds own 8.5% of Beam Therapeutics. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation  in the short term or medium term. Our data shows that FMR LLC is the largest s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-inc-nasdaq-beam-113746956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BEAM","LU2095319765.USD","SQQQ","QLD","USAW.SI","USJW.SI","TSYW.SI","NQmain","PSQ","IE00B64PRP62.GBP","TQQQ","LU2210149790.SGD","BK4535","BK4505","LU2210150020.SGD","BK4112","BK4588","BK4556","QID","NVIW.SI","BK4611",".IXIC","BK4585","BK4139","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2526525917","title":"CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526525917","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526525917?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:50","pubTimestamp":1744321811,"startTime":"0","endTime":"0","summary":"In the latest trading session, CRISPR Therapeutics AG  closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%. Elsewhere, the Dow lost 2.5%, while the tech-heavy Nasdaq lost 4.31%.The the stock of company has fallen by 19.78% in the past month, lagging the Medical sector's loss of 10.85% and the S&P 500's loss of 5.27%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.26, up 11.89% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.24 million, up 947.2% from the year-ago period.Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-215011874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CRSP","BK4556","BK4611","LU1861559042.SGD","LU1861558580.USD","BK4210","AG","BK4588","BK4139"],"gpt_icon":0},{"id":"2526518905","title":"Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526518905","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526518905?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:49","pubTimestamp":1744292940,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc.  shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 45% loss over the past four weeks.The stock surged in response to the broader market rally after President Trump announced a 90-day pause on the sweeping tariffs against non-retaliating countries.This company is expected to post quarterly loss of $1.11 per share in its upcoming report, which represents a year-over-year change of +8.3%. Revenues are expected to be $15.34 million, up 107% from the year-ago quarter.For Beam Therapeutics, the consensus EPS estimate for the quarter has been revised 4.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BEAM going forward to see if this recent jump can turn into more strength down the road.Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-beam-moves-12-134900338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","MGTX","BK4139","BEAM","BK4585","BK4535","BK4588","BK4505","BK4556"],"gpt_icon":0},{"id":"2526398492","title":"Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple","url":"https://stock-news.laohu8.com/highlight/detail?id=2526398492","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526398492?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:42","pubTimestamp":1744206178,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Intellia Therapeutics, Inc.  stands against other stocks under $10 that will triple.As we delve into the discussion on stocks that will triple, we must shed light on the U.S. small-cap stocks, which are struggling amid broader market challenges due to ongoing shifts in tariff policy, affecting investors’ confidence. The Russell index  has fallen over 15% from its peak in November 2024 as of the time of writing this article and is down by nearly 19% on a YTD basis. However, the broader market, mostly consisting of large-cap stocks, has only dropped about 14% on a YTD basis. This gap shows how economic uncertainties and higher interest rates have more impact on smaller companies as they typically carry more debt and feel borrowing costs more acutely.Moreover, industry changes and technological advances offer more opportunities to small-cap companies. While the AI bo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-among-134258664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","QLD","USAW.SI","BK4585","LU1861559042.SGD","MNQmain","TQQQ","BK4139","TSYW.SI","NQmain","USJW.SI","QID","PSQ","NTLA","SQQQ","LU1861558580.USD",".IXIC","BK4556","BK4535","NVIW.SI"],"gpt_icon":1},{"id":"2526937643","title":"CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526937643","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526937643?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:00","pubTimestamp":1744203608,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG  has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -26.2%, compared to the Zacks S&P 500 composite's -13.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 17.7%. The key question now is: What could be the stock's future direction?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-attracting-130008048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4210","BK4556","BK4611","LU1861558580.USD","AG","LU1861559042.SGD","CRSP","BK4139","BK4585"],"gpt_icon":1},{"id":"2525402980","title":"Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525402980","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525402980?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:06","pubTimestamp":1744034788,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc.  on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency  at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress.AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease.Also Read: Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity. Initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previouslyreported in March 2025, establishing clinical proof of concept as a potential treatment for AATD andin vivo base editing.Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated.Single doses of BEAM-302 led to durable dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the 60 mg dose coh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-presents-biomarker-data-140628622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4556","BK4588","BK4505","BEAM","BK4585","BK4611","BK4535"],"gpt_icon":0},{"id":"2525017775","title":"4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017775","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017775?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:09","pubTimestamp":1744027740,"startTime":"0","endTime":"0","summary":"All four of these companies have encountered headwinds recently.Wall Street analysts think their shares have fallen far too much.Some of these drugmakers look attractive, but one seems particularly risky right now.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/07/4-beaten-down-stocks-that-could-skyrocket-by-50-to/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1861558580.USD","BK4585","CRSP","LU1861559042.SGD","BK4139","BK4588","BK4556","BK4611"],"gpt_icon":0},{"id":"2525014386","title":"Beam Therapeutics (BEAM) Gets a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2525014386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525014386?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:16","pubTimestamp":1744024619,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4535","BK4556","BK4505","BK4588","BEAM","BK4139","BK4611"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}